Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pfestroff

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Cancers|November 27, 2021
Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?Sabine Wächter, Pietro Di Fazio, Elisabeth Maurer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 26, 2009
Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imagingOlivia M Merkel, Damiano Librizzi, Andreas Pfestroff, et al.
Plos One|March 19, 2016
Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical TrialAfshin Teymoortash, Andreas Pfestroff, Andrea Wittig, et al.
Cancer|March 6, 2002
A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypesUlrich Wulbrand, Martin Feldman, Andreas Pfestroff, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]Wolfgang P Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
Thyroid : Official Journal of the American Thyroid Association|August 18, 2021
Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid CancerViktoria Florentine Koehler, Elke Berg, Pia Adam, et al.
Annals of Surgery|July 11, 2020
Clinical Presentation, Treatment, and Outcome of Parathyroid Carcinoma: Results of the NEKAR Retrospective International Multicenter StudyChristina Lenschow, Sina Schrägle, Stefan Kircher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 22, 2016
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsKambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cancers|November 27, 2021
Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?Sabine Wächter, Pietro Di Fazio, Elisabeth Maurer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 26, 2009
Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imagingOlivia M Merkel, Damiano Librizzi, Andreas Pfestroff, et al.
Plos One|March 19, 2016
Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical TrialAfshin Teymoortash, Andreas Pfestroff, Andrea Wittig, et al.
Cancer|March 6, 2002
A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypesUlrich Wulbrand, Martin Feldman, Andreas Pfestroff, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]Wolfgang P Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
Thyroid : Official Journal of the American Thyroid Association|August 18, 2021
Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid CancerViktoria Florentine Koehler, Elke Berg, Pia Adam, et al.
Annals of Surgery|July 11, 2020
Clinical Presentation, Treatment, and Outcome of Parathyroid Carcinoma: Results of the NEKAR Retrospective International Multicenter StudyChristina Lenschow, Sina Schrägle, Stefan Kircher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 22, 2016
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsKambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, et al.
Pageof 4